Your browser doesn't support javascript.
loading
Survival prediction of glioblastoma patients using modern deep learning and machine learning techniques.
Babaei Rikan, Samin; Sorayaie Azar, Amir; Naemi, Amin; Bagherzadeh Mohasefi, Jamshid; Pirnejad, Habibollah; Wiil, Uffe Kock.
Afiliación
  • Babaei Rikan S; Department of Computer Engineering, Urmia University, Urmia, Iran.
  • Sorayaie Azar A; Department of Computer Engineering, Urmia University, Urmia, Iran.
  • Naemi A; SDU Health Informatics and Technology, The Maersk Mc-Kinney Moller Institute, University of Southern Denmark, Odense, Denmark.
  • Bagherzadeh Mohasefi J; Department of Computer Engineering, Urmia University, Urmia, Iran. j.bagherzadeh@urmia.ac.ir.
  • Pirnejad H; Erasmus School of Health Policy and Management (ESHPM), Erasmus University Rotterdam, Rotterdam, The Netherlands. pirnejad@eshpm.eur.nl.
  • Wiil UK; Patient Safety Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran. pirnejad@eshpm.eur.nl.
Sci Rep ; 14(1): 2371, 2024 01 29.
Article en En | MEDLINE | ID: mdl-38287149
ABSTRACT
In this study, we utilized data from the Surveillance, Epidemiology, and End Results (SEER) database to predict the glioblastoma patients' survival outcomes. To assess dataset skewness and detect feature importance, we applied Pearson's second coefficient test of skewness and the Ordinary Least Squares method, respectively. Using two sampling strategies, holdout and five-fold cross-validation, we developed five machine learning (ML) models alongside a feed-forward deep neural network (DNN) for the multiclass classification and regression prediction of glioblastoma patient survival. After balancing the classification and regression datasets, we obtained 46,340 and 28,573 samples, respectively. Shapley additive explanations (SHAP) were then used to explain the decision-making process of the best model. In both classification and regression tasks, as well as across holdout and cross-validation sampling strategies, the DNN consistently outperformed the ML models. Notably, the accuracy were 90.25% and 90.22% for holdout and five-fold cross-validation, respectively, while the corresponding R2 values were 0.6565 and 0.6622. SHAP analysis revealed the importance of age at diagnosis as the most influential feature in the DNN's survival predictions. These findings suggest that the DNN holds promise as a practical auxiliary tool for clinicians, aiding them in optimal decision-making concerning the treatment and care trajectories for glioblastoma patients.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glioblastoma / Aprendizaje Profundo Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glioblastoma / Aprendizaje Profundo Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Sci Rep Año: 2024 Tipo del documento: Article País de afiliación: Irán
...